Amvuttra is used in adults to treat polyneuropathy (nerve damage) related to hereditary amyloid transthyretin-mediated (hATTR) amyloidosis. This is a rare genetic (inherited) condition that causes ...

Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Building a Cardiogenic Shock Program at a Large Regional Hospital Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

ATTR is characterised by the formation of amyloid fibril deposits in tissues ... is being developed for both ATTR cardiomyopathy and polyneuropathy. The polyneuropathy indication making it a ...

ATTR amyloidosis is an aggressive, rapidly progressing, debilitating and fatal disease, and the launch of Alnylam's earlier Onpattro (patisiran) in 2018 for polyneuropathy associated with the ...

Onpattro (patisiran) is approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The injection recorded sales of $56.1 million in the reported quarter ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...